Company: INTS
Filing Date: 2025-04-22
Form Type: S-1
Source: 0001628280-25-018892
Chunk: 35

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-22
Form: S-1
Chunk 35
---
 of Common Stock. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis. Each share of Common Stock or Pre-Funded Warrant is being sold together with a Common Warrant to purchase one share of Common Stock. The shares of Common Stock or Pre-Funded Warrants and accompanying Common Warrants will be issued separately. We are also registering the shares of Common Stock issuable from time to time upon exercise of the Pre-Funded Warrants offered hereby and the Common Warrants offered hereby.

#### Common Stock
See the description above under “Description of Our Capital Stock—Common Stock”.

Series B-1 Common Warrants to be Issued in this Offering

The following is a summary of the material terms and provisions of the Series B-1 Common Warrants that are being offered hereby. This summary is subject to and qualified in its entirety by the form of Series B-1 Common Warrant, which will be filed with the SEC as an exhibit to a Current Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus form a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the warrants.

#### Duration and Exercise Price.
The Series B-1 Common Warrants offered hereby will have an exercise price of $1.88 per share (the assumed combined offering price per share of Common Stock and accompanying Common Warrants (the closing price of our Common Stock on Nasdaq on April 21, 2025)). The Series B-1 Common Warrants are exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder Approval will not be required and the Series B-1 Common Warrants will be exercisable on the Initial Exercise Date, at an assumed exercise price equal to $1.88 (equal to the assumed combined public offering price per share of Common Stock and accompanying Common Warrants). The Series B-1 Common Warrants will expire five years from the Initial Exercise Date or the Warrant Stockholder Approval, as applicable. The exercise price and number of shares of Common Stock issuable upon exercise of the Series B-1 Common Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock.

#### Exercis